<DOC DOCNO="nw/wsj/23/wsj_2335@2335@wsj@nw@en@on">
<TEXT PARTNO="000">
<COREF ID="25" TYPE="IDENT"><COREF ID="1" TYPE="APPOS" SUBTYPE="HEAD">Alan Seelenfreund</COREF> , <COREF ID="1" TYPE="APPOS" SUBTYPE="ATTRIB">52 years</COREF> old ,</COREF> was named *-1 *PRO*-3 chairman of <COREF ID="18" TYPE="IDENT">this processor of prescription claims</COREF> , *PRO*-1 succeeding <COREF ID="15" TYPE="IDENT">Thomas W. Field Jr. , 55 , who *T*-2 resigned last month</COREF> .
<COREF ID="15" TYPE="IDENT">Mr. Field</COREF> also had been <COREF ID="20" TYPE="IDENT">chairman of <COREF ID="18" TYPE="IDENT">McKesson Corp.</COREF></COREF> , *PRO*-1 resigning <COREF ID="20" TYPE="IDENT">that post</COREF> after a dispute with the board over corporate strategy .
<COREF ID="25" TYPE="IDENT">Mr. Seelenfreund</COREF> is <COREF ID="31" TYPE="IDENT">executive vice president and chief financial officer of <COREF ID="18" TYPE="IDENT">McKesson</COREF></COREF> and will continue in <COREF ID="31" TYPE="IDENT">those roles</COREF> .
<COREF ID="32" TYPE="IDENT">PCS</COREF> also named <COREF ID="34" TYPE="APPOS" SUBTYPE="HEAD">Rex R. Malson</COREF> , <COREF ID="34" TYPE="APPOS" SUBTYPE="ATTRIB">57</COREF> , <COREF ID="34" TYPE="APPOS" SUBTYPE="ATTRIB">executive vice president at McKesson</COREF> , as a director , *PRO*-1 filling the seat vacated * by <COREF ID="15" TYPE="IDENT">Mr. Field</COREF> .
Messrs. Malson and Seelenfreund are directors of <COREF ID="18" TYPE="IDENT">McKesson , which *T*-1 has an 86 % stake in <COREF ID="32" TYPE="IDENT">PCS</COREF></COREF> .
</TEXT>
</DOC>
